爵士製藥 JAZZ 深 滬
已收盤 11-06 16:00:00 美东时间
234.76
+7.440
+3.27%
華盛通- 最 高237.76
- 今 開226.66
- 成交量 88.76万股
- 最 低 225.50
- 昨 收 227.32
- 總市值 150.69亿
- 52周最高 266.375
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 156.95
- 委 比 -78.21%
- 總股本 6418.91万
- 歷史最高 266.375
- 量 比 0.81
- 振 幅 5.39%
- 歷史最低 31.87
- 每 手 1
- 風險率 33.88%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 苹果、雅诗兰黛、莱迪思半导体均获大行上调目标价
今日重点评级关注：Rosenblatt：维持SiTime"买入"评级，目标价从750美元升至900美元；花旗：维持Madrigal Pharmaceuticals"买入"评级，目标价从725美元升至760美元
11-04 18:17
Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (JAZZ) and Alcon (ALC)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts jus...
11-03 18:40
财报速睇 | 爵士制药 2026财年Q3营收12.43亿美元，同比增长10.4%；归母净利润亏损4.83亿美元，由盈转亏
华盛资讯11月3日讯，爵士制药公布2026财年Q3业绩，公司Q3营收12.43亿美元，同比增长10.4%，归母净利润亏损4.83亿美元，由盈转亏。
11-03 07:02
爵士制药收跌0.71%，成交额2.24亿美元
11月3日，爵士制药（JAZZ）收跌0.71%，报214.44美元，成交额2.24亿美元，市值139.2亿美元。 行情数据 • 开盘价：215.84美元 • 最...
11-03 05:49
Jazz Pharmaceuticals Raises FY2026 Sales Guidance from $4.600B-$4.750B to $4.775B-$4.850B vs $4.719B Est
Jazz Pharmaceuticals (NASDAQ:JAZZ) raises FY2026 sales outlook from $4.600 billion-$4.750 billion to $4.775 billion-$4.850 billion vs $4.719 billion estimate.
11-03 05:08
Jazz Pharmaceuticals Q3 Adj. EPS $(3.88) Misses $(3.86) Estimate, Sales $1.243B Beat $1.208B Estimate
Jazz Pharmaceuticals (NASDAQ:JAZZ) reported quarterly losses of $(3.88) per share which missed the analyst consensus estimate of $(3.86) by 0.52 percent. This is a 147.72 percent decrease over earnings of $8.13 per share from the same period last year. The company reported quarterly sales of $1.243 ...
11-03 05:08
美股大行评级 | 潜在涨幅163.5%！BTIG上调Cullinan Therapeutics目标价至41美元，维持"买入"评级
今日重点评级关注：BTIG：维持Cullinan Therapeutics"买入"评级，目标价从40美元升至41美元；Rosenblatt：维持SK海力士"买入"评级，目标价从320美元升至400美元
10-29 12:30
JP Morgan Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $300
JP Morgan analyst Jessica Fye maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and raises the price target from $276 to $300.
10-29 03:12
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026
Zymeworks Inc. presented promising clinical data for ZW191, an antibody-drug conjugate targeting folate receptor alpha (FRα), in patients with platinum-resistant ovarian cancer (PROC). The study showed a confirmed objective response rate (cORR) of 64.5% at the 6.4 mg/kg dose and 55.3% at 9.6 mg/kg in high-grade serous PROC patients. ZW191 demonstrated meaningful anti-tumor activity across all FRα expression levels, with a median duration of respo...
10-24 06:30
